Samsung Biologics Signs Contract Worth 18.3 Billion KRW with US Pharmaceutical Company
[Asia Economy Reporter Seo So-jeong] Samsung Biologics announced on the 3rd that it has signed a contract worth 18.3 billion KRW for contract manufacturing of pharmaceuticals with a US pharmaceutical company.
This contract amounts to 2.61% of last year's sales, and the contract period is until December 31, 2030.
Hot Picks Today
!["Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"](https://cwcontent.asiae.co.kr/asiaresize/93/2026081215431278523_1786516992.gif)
"Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"
- Thought It Was a Patriot’s Calligraphy, But Possibly a Pro-Japanese Collaborator’s? National Museum Issues Apology
- "If You Don't Buy Now, You'll Be Too Late"... Office Workers Rush for Golden Holiday as Flight and Hotel Reservations Heat Up
- In Response to Consecutive Violent Incidents in Gyeongsan, Gyeongbuk Police Reinforce Prevention Patrols for Enhanced Security
- "Controversy Over Female YouTuber Who Filmed in Mixed-Gender Bath Despite Knowing Filming Was Prohibited"
The company stated, "This contract is the formal agreement following the 'Letter of Intent for Biopharmaceutical Production' signed on March 31," adding, "If the client's product development succeeds, the confirmed contract amount is expected to increase to $21,221,800, and if the client's demand increases in the future, the confirmed contract amount may further increase after consultation." They also added, "The contracting party will be disclosed after December 31, 2023, due to business confidentiality reasons."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
